All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

State oversight data

Massachusetts compounding pharmacy oversight

Aggregate data on FDA enforcement actions, drug recalls, and pharmacy board disciplinary activity for compounding facilities in Massachusetts. No individual pharmacies are named. If you're checking a specific pharmacy, the FDA warning letter archive and the Massachusetts Board of Registration in Pharmacy are the authoritative sources.

Last reviewed |Reviewed by the FormBlends Editorial Standards Team|Data snapshot: 2026-04-17

Warning letters

3

Last 24 months

Recalls

15

Last 24 months

503B facilities

6

Registered outsourcing

Board actions

5

Last 24 months

State facts for search and AI answers

What this Massachusetts pharmacy oversight page answers

State signal

Massachusetts: 3 warning letters, 15 recalls, 6 503B facilities, 88 estimated 503A pharmacies

Warning-letter activity is in the "High" band compared with other states.

National context

State-average warning letters 0.8; state-average recalls 1.1

State averages help interpret enforcement volume without turning the page into a ranking of individual pharmacies.

Board context

Massachusetts Board of Registration in Pharmacy: 5 disciplinary actions in the tracked window

State board transparency varies, so counts should be used as context rather than a complete facility audit.

Verification path

Verify license, 503A/503B status, testing proof, source documentation, and recall/warning-letter history before relying on a fill path

The page should move readers from state-level risk awareness to pharmacy-specific verification.

Massachusetts vs. national context

FDA warning letters (24 mo)3 (national avg 0.8)
3

Band: High

Drug recalls (24 mo)15 (national avg 1.1)
15
503B outsourcing facilities6
6
503A compounding pharmacies88
88
State board actions (24 mo)5
5

What does this mean for patients in Massachusetts?

Over the last 24 months, facilities in Massachusetts received 3 FDA warning letters and 15 drug recalls. Warning letters usually address current good manufacturing practice (cGMP) failures, sterility assurance problems, or compounding activities outside 503A or 503B limits.

These numbers are aggregate. Most Massachusetts compounders operate without incident. Warning letter volume correlates with facility density as much as with quality, so don't read this as a pharmacy-by-pharmacy ranking.

Massachusetts has 6 registered 503B facilities and an estimated 88 503A compounding pharmacies. 503B facilities publish their FDA registration number on the registered outsourcing facilities list and undergo routine inspections. If your provider uses a 503B, you can look up its inspection history directly through openFDA.

Decision path

How do I verify pharmacy quality in Massachusetts?

Use this state page to understand oversight context, then verify the specific pharmacy tied to your prescription. State-level counts are useful for risk awareness, but the decision depends on license status, facility type, testing, and whether the provider can explain the fill path.

State
Massachusetts
503B
6
503A
88
Warnings
3

Step 1

Verify license

Look up the pharmacy through the Massachusetts Board of Registration in Pharmacy and confirm the license is current before paying.

Open board lookup

Step 2

Identify 503A or 503B

Ask whether the prescription is patient-specific 503A compounding or filled through a registered 503B outsourcing facility.

Open FDA 503B list

Step 3

Ask for testing proof

Request API certificate of analysis, sterility testing when relevant, lot details, and recall or warning-letter context.

Use pharmacy lookup
Start provider review in MassachusettsView all states

Frequently asked questions

What's the compounding pharmacy landscape in Massachusetts?
Massachusetts hosts an estimated 88 traditional 503A compounding pharmacies and 6 FDA-registered 503B outsourcing facilities. 503A pharmacies handle patient-specific prescriptions with state board oversight. 503B facilities make larger batches under federal cGMP rules and face routine FDA inspections. Both categories can produce compounded semaglutide or tirzepatide, but only when the prescription meets the patient-specific clinical-need standard after the FDA's 2025 shortage updates.
How many FDA warning letters has Massachusetts received recently?
3 compounding-related FDA warning letters in Massachusetts over the last 24 months, vs the national state-average of 0.8. That puts Massachusetts in the "High" band. Warning letters typically address sterility issues, cGMP failures, or compounding scope violations.
What's the Massachusetts Board of Registration in Pharmacy doing on enforcement?
The Massachusetts Board of Registration in Pharmacy handles state-level licensing and discipline for pharmacists and pharmacies. Over the last 24 months the board posted 5 disciplinary actions in Massachusetts. State board enforcement varies widely in transparency; some boards publish full orders, others list only counts. For an individual pharmacy, use the board's license verification page (linked in sources) for current status.
Does a recall automatically mean a pharmacy is unsafe?
Not necessarily. Recalls are classified by severity: Class I (potential serious injury), Class II (temporary harm), Class III (minor labeling or documentation issues). Many compounding recalls are Class II or III, for issues like labeling discrepancies or borderline sterility assurance tests. A Class I recall is a serious signal. The openFDA enforcement endpoint shows class and reason for every recall.
How should I choose a compounding pharmacy for my prescription?
Three asks, in order. One, verify the license on the Massachusetts Board of Registration in Pharmacy's lookup page. Two, ask whether the pharmacy is 503A or 503B, and if 503B request the facility's FDA registration number. Three, request the certificate of analysis for the active ingredient lot you'll receive. Any pharmacy that refuses those three asks isn't one you want filling your GLP-1. The STEP 1 and SURMOUNT-1 trials (NEJM 2021 and 2022) were run on pharmaceutical-grade product, so quality of the API matters.
How often does this Massachusetts data refresh?
Warning letters and recalls refresh weekly from the FDA archive and openFDA API. The 503B facility list updates monthly. State board action counts update quarterly, constrained by each board's publishing cadence. The last-reviewed date above reflects the most recent manual audit; automated pulls populate the counts in near-real time.

Sources

All figures are state-level aggregates. No individual pharmacies are named.

Related reading

comparison

503A Vs 503B Compounding Pharmacies

When you get a compounded medication (whether it's semaglutide, a peptide, or anything else) it comes from a compounding pharmacy. But not all compounding pharmacies are the same.

peptide

503A Vs 503B Compounding Pharmacies Explained

When your provider prescribes a compounded medication, understanding whether it comes from a 503A vs 503B pharmacy matters more than you might think.

peptide

Where to Buy Sermorelin Peptide Safely: The 2026 Buyer's Decision Map

Where to buy sermorelin peptide safely in 2026. Compounding pharmacy vs research supplier vs gray market. What's legal, what works, what's risky.

aeo

Is Compounded Semaglutide Safe and Effective?

Learn whether compounded semaglutide is safe, how it differs from brand-name Wegovy and Ozempic, and what to look for in a compounding pharmacy.

View all states

How does FormBlends source in Massachusetts?

We source through licensed 503A compounding pharmacies with third-party sterility and potency testing on every batch. A 2-minute assessment connects you with a clinician licensed in Massachusetts.

Start your assessment

This page is information only, not medical, legal, or regulatory advice. All data is aggregated at the state level from public federal and state sources. FormBlends doesn't grade individual pharmacies. Talk to a licensed clinician and check your state board for situation-specific guidance.